J&J gained rights to the FcRn blocker nipocalimab when it acquired Momenta Pharmaceuticals in August 2020 for $6.5 billion.

Eli Lilly this week announced plans to sell single-dose vials of its weight loss drug Zepbound directly to consumers. Novo ...

In agreeing with Novo Nordisk and Eli Lilly, Pennsylvania judge Karen Spencer Marston said the court should first settle ...

The pharma continued its clinical losing streak on Thursday with the announcement that it is discontinuing late-stage studies ...

The vaccine maker is competing with well-established rivals in markets that have a mix of demand issues as well as commercial ...

Neurocrine Biosciences’ potential competitor to Bristol Myers Squibb’s KarXT improved symptoms of schizophrenia in a Phase II ...

Armed with new late-stage data on reducing low-density lipoprotein cholesterol, Novartis is positioning its siRNA therapy ...

In its legal complaint, filed in the District Court for New Jersey, Regeneron alleges that Sandoz failed to provide it with ...

Navigator Medicine is looking to push its lead asset NAV-240 targeting immune-mediated diseases through to clinical studies ...

In Texas, the Plano City Council approved a development agreement that supports a planned project that would bring over 3 ...

The Switzerland layoffs are the latest in Bayer’s 2024 workforce reductions, which already include 1,500 people and nearly ...

The company joins Eli Lilly in offering its own digital platform to more directly connect to patients, allowing them easier ...